Global Optogenetics Market - 2022-2029

Global Optogenetics Market - 2022-2029

Market Overview

The Global Optogenetics Market is expected to grow at a high CAGR during the forecasting period (2022-2029).

Optogenetics is a scientific approach that includes a combination of genetics and optics technologies. It is primarily used for controlling and monitoring the biological functions of neurons and other types of cells with light sensors. This information provides insights into individual behavior and physiology, including movement, learning, memory, navigation, metabolism, respiration, and sensor processing. Optogenetics is widely used in neuroscience for the modulation of neural circuits with a high degree of precision and specificity.

Market Dynamics

The global optogenetics market growth is driven by technological advancements, the potential diagnostic tool in the field of neurosciences, the rapid growth of advanced technologies, and the increasing use of multimodal imaging. The introduction of fiber-coupled light-emitting diode (LED) for being incorporated into the implants to enable untethered light delivery is also driving the market growth in the forecast period.

The rapid growth of advanced technology is driving the market growth in the forecast period

Optogenetics technology has revolutionized neuroscience by allowing researchers to control specific neurons in experimental animals. The ability to control neurons has revealed information about brain pathways involved in diseases such as depression, obsessive-compulsive disorders, Parkinson's disease, and other conditions. In neural research, optogenetic methods for monitoring synaptic activity have proven to be extremely useful in a number of neurological diseases.

It allows researchers to study how the neurological activity patterns within specific brain cells give rise to thoughts, behaviors, and memories at an unprecedented precision level. Thus, it helps to find cures and treatments for neurological and psychiatric disorders, such as depression, addiction, schizophrenia, and Parkinson's disease. For instance, according to the article published in the Nature communication in May 2020, titled ”Deep brain stimulation-guided optogenetic rescue of parkinsonian symptoms” the precision of optogenetics holds the promise of improved normalization of circuits that are dysfunctional in Parkinson's disease as well as its diagnosis, while the use of light rather than electricity (as in deep brain stimulation) may reduce the risk of unintended effects caused by non-specific influences. Thus, the use of optogenetics in the diagnosis of Parkinson's disease has proven to be a potential tool used for diagnosis of the brain activity in Parkinson's disease. Thus, these factors are driving the growth of the market in the forecast period.

The dearth of optogenetics with integrated safety features will hamper the market growth

However, lack of awareness and the high cost of technology is the major restraining factor for the growth of the market over the forecast period. Generally, LEDs are limited to several hundred megabits/second links while lasers are good for 25-50 gigabits per second links when direct modulated. Thus, the low efficiency of optical fibers limits the use of LEDs for certain applications.

COVID-19 Impact Analysis

The COVID-19 pandemic globally is expected to have a significant impact on the optogenetics market. According to the article published by PUS University in February 2022, by Shanet Suzan Alex, SARS-CoV-2 causes neurological abnormalities as well as respiratory symptoms, with an 85% occurrence rate in Alzheimer's patients. Furthermore, as per the same source, SARS-CoV-2 infiltrated COVID-19 patients' cognitive centers, causing Alzheimer's-like phenotypes in those with no underlying conditions and exacerbating Alzheimer's neuropathology in those with Alzheimer's and autism. As a result of the COVID-19 associated with neurological disorders, the rate of mortality has increased, and the market has been significantly impacted.

Segment Analysis

The Light-emitting Diode (LED) segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)

LEDs are found to surpass lasers in every aspect, as they are cheaper, smaller, more reliable, and easier to control. They are being incorporated into implants, allowing untethered light delivery. Factors such as investment in technology, product launches, and research studies in the segment are expected to drive the segmental growth subsequently driving the market. For instance, In February 2020, a project was launched with a EUR 3.6 million grant to treat neurological conditions such as Alzheimer’s and Huntington’s disease by making brain cells controllable with red light. A laser can control the neurons and boost cognition. Simultaneously, brain cell activity can be monitored non-invasively using a spectrometer. Thus, the launch of such projects promotes technological innovation and advancement in the studied market, thus contributing to market growth.

Additionally, in January 2021, SYMBXX initiated two clinical trials, in Adelaide, Australia, and Toronto, Canada for developing laser light therapies to reduce the debilitating symptoms of Parkinson’s disease. The clinical trials focused on seeking regulatory approvals will drive the market during the forecast period. Moreover, according to a study “Ultrafast laser-based transient perforation of cellular membranes for in-vivo neuromodulation” published in January 2022, a near-infrared ultrafast laser micro irradiation platform can be used for delivering gene encoding for neuroprotective and anti-angiogenic Pigment epithelium-derived factor (PEDF) molecule to the retina that exhibited protection from different insults. The research studies expanding the scope of lasers will also contribute to the growth of the market in the forecast period.

Geographical Analysis

North America region holds the largest market share of the global optogenetics market

North America has the largest market share in the forecast period owing to the increase in the use of optogenetic devices, primarily in academic and research labs, the high burden of chronic diseases in the region coupled with the collaborations and new product launches by the key market players in the region.

Increasing government initiatives for the neurological field is one of the key factors for the growth of the market. Increasing funding allows multiple players to enter the market and provide innovative solutions to cater to the need of the patient. For instance, as per the National Center for Chronic Disease Prevention and Health Promotion (January 2021), 6 in 10 adults in the United States have a chronic disease and 4 in 10 adults have two or more chronic diseases and these conditions are posing around USD 3.8 trillion of healthcare costs on the country’s healthcare system every year that is expected to have a significant impact on the growth of the studied market.

Similarly, according to the report published by Alzheimer's Impact Movement in July 2020, more than 5 million Americans are living with Alzheimer’s and an estimated 16 million are providing unpaid care. Alzheimer’s is estimated to cost the nation USD 305 billion in 2020 including USD 206 billion in Medicare and Medicaid payments. The increasing patient population requires more care which increases the demand for optogenetics products. Thus, increasing the growth of the market. Additionally, Collaborations and agreements are another reason for the growth of the market. For instance, in September 2021, NeuroLux, Inc. announced its exclusive partnership with TSE Systems, under which the company will integritsheir wireless technology with TSE System’s IntelliCage and PhenoMaster platforms, providing optogenetic, pharmacology, telemetry, and other capabilities for cutting edge behavioral neuroscience research. Such collaborations increase innovation due to the synchronization of key players’ resources which increases the growth of the market in the forecast period.

Competitive Landscape

The optogenetics market is a moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include the Hubner group (Cobolt Inc.), Coherent Inc., Gensight Biologics, Laserglow Technologies, Noldus Information Technology, Judges Scientific Plc (Scientifica), Shanghai Laser & Optics Century Co. Ltd, Bruker Corporation, Thorlabs Inc., Regenxbio Inc among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the optogenetics market globally. For instance, in September 2021, Novartis acquired Arctos Medical, expanding its optogenetics portfolio to bring gene therapies to patients with severe vision loss.

Laserglow Technologies

Overview:

Laserglow Technologies is an optoelectronics company headquartered in Toronto, Ontario, Canada, specializing in the sale of lasers, particularly DPSS and collimated diode lasers.

Product Portfolio:

447 nm Collimated Diode Laser System: The LRD-0447 Series of Collimated Diode (Semiconductor) Lasers are ideal for applications requiring a short wavelength of 447 nm and output power levels of 5 mW to 20 W with a high level of long-term output power stability and long operating lifetime at a very competitive cost.